A prospective study of risk factors for pulmonary embolism in women

Author(s): Goldhaber SZ, Grodstein F, Stampfer MJ, Manson JE, Colditz GA, et al.


Objective: To investigate risk factors for pulmonary embolism in women.

Design: Prospective study based on biennial, mailed questionnaires.

Setting: Nurses' Health Study with 16 years of follow-up from 1976 to 1992.

Patients: A group of 112822 women aged 30 to 55 years in 1976, free from diagnosed cardiovascular disease or cancer at baseline. Overall, there were 1619770 person-years of follow-up.

Measurements: Based on self-report and medical records, we documented 280 cases of pulmonary embolism, of which 125 were primary (no identified antecedent cancer, trauma, surgery, or immobilization). Information on height, weight, cigarette smoking, hypertension, diabetes, and hypercholesterolemia was collected by questionnaire.

Results: In multivariate analysis, obesity, cigarette smoking, and hypertension were independent predictors of pulmonary embolism. Specifically, obese women (body mass index > or = 29.0 kg/m2) had an increased risk of primary pulmonary embolism (multivariate relative risk=2.9; 95% confidence interval [CI], 1.5-5.4). Heavy cigarette smokers also had an increased risk of primary pulmonary embolism. The relative risk (RR) of primary pulmonary embolism was 1.9 (95% CI, 0.9-3.7) for women currently smoking 25 to 34 cigarettes per day and 3.3 (95% CI, 1.7-6.5) for those smoking 35 cigarettes or more daily as compared with never smokers. Hypertension, even after adjustment for body mass index, was also associated with an increased risk of primary pulmonary embolism (RR=1.9; 95% CI, 1.2-2.8). High serum cholesterol levels (RR=1.1; 95% CI, 0.62-1.8) and diabetes (RR=0.7; 95% CI, 0.3-1.9) did not appear to be related to primary pulmonary embolism.

Conclusion: These prospective data indicate that obesity, cigarette smoking, and hypertension are associated with increased risk of pulmonary embolism in women. Control of these risk factors will decrease risks of pulmonary embolism as well as coronary heart disease.

Similar Articles

A prospective study of the incidence of deep-vein thrombosis within a defined urban population

Author(s): Nordström M, Lindblad B, Bergqvist D, Kjellström T

A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism

Author(s): Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al.

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

Author(s): Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, et al.

Age, an independent risk factor for thrombosis

Author(s): MahéI, Caulin C, Bergmann JF

Immobilization and the risk of venous thromboembolism

Author(s): Pottier P, Hardouin JB, Lejeune S, Jolliet P, Gillet B, et al.

Management of pulmonary embolism in a cardiology department

Author(s): OuldzeinH, Nourredine A, Cherradi R, Rahal N, Mechmeche R, et al.

Prolonged work- and computer-related seated immobility and risk of venous thromboembolism

Author(s): Healy B, Levin E, Perrin K, Weatherall M, Beasley R

Venous thromboembolism in Jamaican women: experience in a university hospital in Kingston

Author(s): Fletcher HM, Wharfe G, Williams NP, Pedican M, Brooks A, et al.

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Author(s): Geerts WH, Pineo GF, Heit JA, Bergqvist D, Lassen MR, et al.

Epidemiology of acute deep vein thrombosis

Author(s): BulgerCM, Jacobs C, Patel NH

Hormonal contraception and risk of venous thromboembolism: national follow-up study

Author(s): Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C

Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study

Author(s): Rosing J, Middeldorp S, Curvers J, Christella M, Thomassen LG, et al.

Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study

Author(s): Middeldorp S, Meijers JC, van den Ende AE, van Enk A, Bouma BN, et al.

Impact of progestagens on activated protein C (APC) resistance among users of oral contraceptives

Author(s): Alhenc-Gelas M, Plu-Bureau G, Guillonneau S, Kirzin JM, Aiach M, et al.

Effect of four different oral contraceptives on various sex hormones and serum-binding globulins

Author(s): Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, et al.

[Upper limb deep venous thrombosis]

Author(s): Benhamou Y, Marie I, David N, Gbaguidi X, Cailleux N, et al.

Old and new risk factors for upper extremity deep venous thrombosis

Author(s): Blom JW, Doggen CJ, Osanto S, Rosendaal FR

Homocysteine and vascular disease

Author(s): Hankey GJ, Eikelboom JW

The long-term clinical course of acute deep venous thrombosis

Author(s): Prandoni P, Lensing AW, CogoA, Cuppini S, Villalta S, et al.

The duration of oral anticoagulant therapy after a second episode of venous thromboembolism

Author(s): Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, et al.